Considerations Following Locoregional Therapy in HCC
Considerations Following Locoregional Therapy in HCC
May 2015
- 64-year old obese female presented with fatigue and unexplained weight loss
- History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
- Lab results: AFP= 1,500 IU/ml
- ECOG=1; Child-Pugh A
- CT revealed 1 large liver mass, right side of liver close to a major blood vessel
- No extrahepatic disease
- Liver-directed therapy with DEB-TACE was performed
- Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
- Patient had a complete response
- AFP= 200 IU/ml at follow up
February 2017
- Follow-up imaging showed progression and evidence of bone metastases
- Therapy was initiated with sorafenib at 400 mg BID
- Follow-up testing showed liver decompensation
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
